

**Serveur Académique Lausannois SERVAL [serval.unil.ch](http://serval.unil.ch)**

## **Author Manuscript**

**Faculty of Biology and Medicine Publication**

**This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.**

Published in final edited form as:

**Title:** Trends in vitamin, mineral and dietary supplement use in Switzerland. The CoLaus study.

**Authors:** Marques-Vidal P, Vollenweider P, Waeber G

**Journal:** European journal of clinical nutrition

**Year:** 2016 Aug 10

**DOI:** 10.1038/ejcn.2016.137

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

1 **Trends in vitamin, mineral and dietary supplement use in Switzerland. The CoLaus study.**

2 **Running title:** trends in vitamin/mineral supplement use

3 Pedro Marques-Vidal, MD, PhD; Peter Vollenweider, MD and Gérard Waeber, MD

4 Department of Internal Medicine, Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland

5 **Authors' emails:**

6 Pedro Marques-Vidal Pedro-Manuel.Marques-Vidal@chuv.ch

7 Peter Vollenweider Peter.Vollenweider@chuv.ch

8 Gérard Waeber Gerard.Waeber@chuv.ch

9 **Address for correspondence and reprints**

10 Pedro Marques-Vidal

11 Department of Internal Medicine, BH10-642

12 Internal Medicine

13 Lausanne University Hospital (CHUV)

14 Rue du Bugnon 46

15 1011 Lausanne

16 Switzerland

17 Phone : +41 21 314 09 34

18 Email : Pedro-Manuel.Marques-Vidal@chuv.ch

19 **Word count:** 3316

20 **Number of tables:** 4 **Figures:** 1 **References:** 41

21 **Number of online supporting materials:** 1 file with 7 tables

23 **CONFLICT OF INTEREST**

24 PV and GW received funding from the Swiss National Science Foundation (Bern, Switzerland);  
25 GlaxoSmithKline (Philadelphia, PA, USA) and the Faculty of Biology and Medicine of Lausanne (Lausanne,  
26 Switzerland) to conduct the CoLaus study. PMV indicates no conflict of interest.

28 **ABSTRACT**

29 **Background:** vitamin/mineral (VMS) and dietary supplements (DS) use is common in Switzerland, but  
30 nothing is known regarding the factors associated with their initiation, discontinuation or continuation of  
31 intake.

32 **Methods:** prospective study conducted between 2003-6 and 2009-12 in Lausanne, Switzerland among 4676  
33 participants (2525 women, age range 35-75 years). VMS were defined as single or  
34 multivitamin/multimineral preparations; DS were defined as any dietary supplement.

35 **Results:** VMS use was 20.6% at baseline and 20.3% at follow-up ( $p=0.69$ ): 559 (12.0%) participants  
36 discontinued; 545 (11.7%) initiated and 404 (8.6%) continued VMS use. On multivariable analysis, men had  
37 a lower relative risk ratio (RRR) of discontinuing, initiation or continuing; older age and being physically  
38 active were associated with a higher RRR of initiation or continuing; lower education and higher body mass  
39 index were associated with a lower RRR of discontinuing or continuing of VMS.

40 DS use decreased from 10.4% to 6.8% ( $p<0.001$ ): 405 (8.7%) participants discontinued; 239 (5.1%) initiated  
41 and 81 (1.7%) continued DS use. On multivariable analysis, men had a lower RRR of discontinuing,  
42 initiation or continuing; older age had a higher RRR of initiation, discontinuing or continuing; being  
43 physically active was associated with a higher RRR of initiation or continuing; Swiss citizens and former  
44 smokers had a higher RRR of discontinuing.

45 **Conclusion:** VMS use is stable in the Lausanne population, while DS use appears to be decreasing.  
46 Individuals can be categorized either as users or non-users depending on the study period, and consistent  
47 users are only a small fraction of prevalent users.

48 **Abstract word count: 249**

49 **Keywords:** supplements; epidemiology; prospective study; discontinuing; persistence; Switzerland.

50

51 **INTRODUCTION**

52 Vitamin and mineral supplements (VMS) are taken by a significant fraction of the general population  
53 <sup>1-5</sup>, although their health benefits are questionable <sup>6-8</sup>. If some VMS might be of interest (i.e. iron for anaemia  
54 and calcium/vitamin D for osteoporosis), several studies suggested that VMS either have no effect <sup>9</sup> or even  
55 increase total mortality <sup>10</sup>. Still, despite recommendations against the use of specific vitamins to prevent  
56 disease <sup>11</sup>, the prevalence of VMS use is increasing in Europe and the USA <sup>12-14</sup>. Interestingly, VMS and  
57 dietary supplements (DS) use appears to be a fairly unstable behaviour in the general population, with high  
58 rates of initiation or discontinuing <sup>15</sup>. Several socio-demographic characteristics such as female gender, older  
59 age and lower body mass index have been shown to be associated with consistent VMS use <sup>15</sup>, but the  
60 number of studies that assessed trends and determinants of VMS and DS use are relatively scarce <sup>15, 16</sup>.

61 In a previous study, we showed that a sizable fraction of the Lausanne population consumed VMS or  
62 DS <sup>17</sup>. We now assessed trends in VMS and DS use and the factors associated with initiation, discontinuing  
63 and persistence of in VMS and DS use in the population of Lausanne, Switzerland.

64 **MATERIALS AND METHODS**

65 *Sampling*

66 The CoLaus Study is a prospective study aiming to assess the prevalence of cardiovascular risk  
67 factors and to identify new molecular determinants of these risk factors in the population of the city of  
68 Lausanne, Switzerland. The sampling procedure of the CoLaus Study has been described previously <sup>18</sup>. In  
69 summary, a simple, non-stratified random sample of the overall population of Lausanne was drawn. The  
70 following inclusion criteria were applied: (a) written informed consent and (b) willingness to take part in the  
71 examination and to provide blood samples. Recruitment began in June 2003 and ended in May 2006 and  
72 included 6184 Caucasian participants. The evaluation included an interview, a physical exam, blood  
73 sampling and a set of questionnaires. The follow-up was performed between April 2009 and September  
74 2012, five and a half years on average after the collection of baseline data and was similar to the baseline  
75 evaluation.

76 *Vitamin/mineral and dietary supplements*

77 Vitamin/mineral supplements were defined as previously <sup>17</sup>. VMS and DS, including omega-3  
78 supplements, were identified. Specific combinations of calcium and vitamin D were also identified.

79 For each group (VMS and DS) users were categorized as never (absent at baseline and follow-up),  
80 initiators (absent at baseline but present at follow-up), discontinuers (present at baseline but absent at follow-  
81 up) and continuers (present at baseline and follow-up) as performed in other studies conducted in  
82 antihypertensive drug treatment <sup>19, 20</sup>. In the prospective survey, drugs prescribed by a doctor were  
83 differentiated from those bought over-the-counter. As calcium + vitamin D supplements might be prescribed  
84 for osteoporosis prevention and iron ± vitamin B<sub>12</sub> for anaemia, sensitivity analyses were carried excluding  
85 participants taking such combinations. Also for sensitivity analyses, participants were categorized as never,  
86 inconsistent (initiators or discontinuers) or consistent (continuers) users, as performed previously <sup>15</sup>.

87 *Other data*

88 Educational level was categorized into mandatory school, apprenticeship, high school and university.  
89 Marital status was categorized into single/divorced/widowed and married/cohabitating. Country of birth was  
90 categorized into Swiss-born and born in another country. Smoking status was defined as never, former and  
91 current. . A participant was considered as physically active if he/she practiced at least twice per week leisure-  
92 time physical activities with a minimal duration of 20 minutes.

93 As presence of cardiovascular risk factors has been associated with initiation or maintenance of  
94 VMS <sup>15</sup>, awareness of hypertension, dyslipidemia or diabetes was considered if the participant responded  
95 positively to the questions “did a doctor tell you that you were hypertensive / had high cholesterol levels /  
96 were diabetic?” respectively. No data was collected regarding other diseases such as arthrosis, cancer or  
97 osteoporosis.

98 Body weight and height were measured with participants standing without shoes in light indoor  
99 clothes. Body weight was measured in kilograms to the nearest 100 g using a Seca<sup>®</sup> scale, which was  
100 calibrated regularly. Height was measured to the nearest 5 mm using a Seca<sup>®</sup> height gauge. Overweight was  
101 defined as body mass index (BMI)  $\geq 25$  and  $< 30$  kg/m<sup>2</sup> and obesity as BMI  $\geq 30$  kg/m<sup>2</sup>. As the number of

102 underweight (BMI<18.5 kg/m<sup>2</sup>) participants was very small (N=83 or 1.8% of the total sample), they were  
103 included in a “normal + underweight” category.

#### 104 *Statistical analysis*

105 Participants were excluded if (a) they did not participate in the follow-up survey and (b) they had any  
106 missing socio-demographic data. Statistical analyses were performed using Stata version 13.1 for windows  
107 (Stata Corp, College Station, TX, USA). Descriptive results were expressed as number of participants  
108 (percentage) or as mean±standard deviation. Bivariate analyses were performed using chi-square for  
109 categorical variables and Student’s t-test or analysis of variance for continuous variables. For continuous  
110 variables, post-hoc pairwise comparisons using the method of Scheffe were performed when the results of  
111 the ANOVA were statistically significant. In agreement with a previous study <sup>15</sup>, multivariable analysis was  
112 performed with multinomial logistic regression using never users as the reference; the results were expressed  
113 as relative risk ratio (RRR) and 95% confidence interval (CI). Multi-collinearity of the dependent variables  
114 was tested using the collin function of Stata; variance inflation factors between 1.01 and 1.20 were obtained,  
115 suggesting that multi-collinearity was not present. Tests were two-sided and statistical significance was  
116 assessed for p<0.05.

#### 117 *Ethics statement*

118 The CoLaus study was approved by the Institutional Ethics Committee of the University of  
119 Lausanne. The study was conducted according to the Declaration of Helsinki and all participants provided  
120 written informed consent prior to participating.

## 121 **RESULTS**

#### 122 *Selection procedure and characteristics of participants*

123 Of the initial 6184 participants at baseline, 1501 (24.3%) did not participate in the follow-up survey  
124 and 7 (0.1%) had missing socio-demographic data. The selection procedure is summarized in **Figure 1** and  
125 the comparison between included and excluded participants is summarized in **supplemental Table 1**.  
126 Excluded participants were older, less frequently women, had a lower educational level, were less frequently  
127 born in Switzerland, were more frequently smokers, sedentary or obese and had a higher prevalence of self-  
128 reported hypertension and diabetes than included participants. Prevalence of VMS and DS use was also  
129 lower among excluded participants (**supplemental table 1**).

130 *Trends and determinants of vitamin/mineral supplement use*

131 Prevalence of VMS use was 20.6% at baseline and 20.3% at follow-up (p=0.69). During the 5.5 year  
132 study period, 559 (12.0%) participants discontinued; 545 (11.7%) initiated and 404 (8.6%) continued VMS  
133 use, while 3168 (67.8%) did not use any VMS at baseline and follow-up.

134 The bivariate associations between socio-demographic and clinical factors and being never using,  
135 initiating, discontinuing or continuing VMS are summarized in **supplemental table 2**. Significant  
136 associations were found with gender, age, educational level, marital status, Swiss citizenship, physical  
137 activity and BMI categories. These associations were partly confirmed by multivariate analysis, the results of  
138 which are summarized in **table 1**. Men had a lower RRR of discontinuing, initiating or continuing VMS use.  
139 Older age and being physically active were associated with a higher RRR of initiating and continuing VMS  
140 use. Having a lower education or a higher BMI was associated with a lower RRR of discontinuing and  
141 continuing VMS use. Finally, presence of reported dyslipidemia was associated with a higher RRR of  
142 continuing VMS use (**table 1**). Similar findings were obtained when the analysis was split by gender (not  
143 shown).

144 *Trends and determinants of dietary supplements use*

145 Prevalence of DS use was 10.4% at baseline and decreased to 6.8% at follow-up (p<0.001). During  
146 the 5.5 year study period, 405 (8.7%) participants discontinued; 239 (5.1%) initiated and 81 (1.7%)  
147 continued DS use, while 3951 (84.5%) did not use any DS at baseline and follow-up.

148 The bivariate associations between socio-demographic and clinical factors and being never using,  
149 initiating, discontinuing or continuing DS are summarized in **supplemental table 3**. Significant associations  
150 were found with gender, age, marital status, Swiss citizenship, smoking status, physical activity and BMI  
151 categories. These associations were partly confirmed by multivariate analysis, the results of which are  
152 summarized in **table 2**. Men had a lower RRR of discontinuing, initiating or continuing DS use. Older age  
153 was associated with a higher RRR of initiating, discontinuing and continuing DS use. Being physically active  
154 was associated with a higher RRR of initiating and continuing DS use. Swiss citizenship and being former  
155 smoker was associated with a higher RRR of discontinuing DS use (**table 2**). Similar findings were obtained  
156 when the analysis was split by gender (not shown).

157 *Sensitivity analyses*

158           The results of the sensitivity analysis on VMS use excluding calcium and vitamin D or iron and  
159 vitamin B<sub>12</sub> combinations were similar to those obtained when the analysis included all VMS, except that  
160 some associations were no longer significant due to smaller sample sizes (not shown).

161           The results of the sensitivity analysis on never, inconsistent (initiating or discontinuing) and  
162 consistent (continuing) use of VMS are summarized in **supplemental tables 4 and 5**. On bivariate analysis,  
163 inconsistent use of VMS was associated with age, BMI, gender, educational level, marital and physical  
164 activity status (**supplemental table 4**). Multivariate analysis showed that participants of male gender, lower  
165 education, married or obese had a lower RRR of inconsistent users, while older or physically active  
166 participants had a higher RRR of inconsistent use (**supplemental table 5**). Similar findings were obtained  
167 when the analysis was split by gender (not shown).

168           The results of the sensitivity analysis on never, inconsistent (initiating or discontinuing) and  
169 consistent (continuing) use of DS are summarized in **supplemental tables 6 and 7**. On bivariate analysis,  
170 inconsistent use of DS was associated with age, BMI, gender, educational level, country of birth, smoking,  
171 marital and physical activity status (**supplemental table 6**). Multivariate analysis showed that participants of  
172 male gender or of lower education had a lower RRR of inconsistent use, while older, former smoker or  
173 physically active participants had a higher RRR of inconsistent use (**supplemental table 7**). Similar findings  
174 were obtained when the analysis was split by gender (not shown).

175 **DISCUSSION**

176           VMS use changes with time, a sizable number of users discontinuing during a 5.5 year follow-up,  
177 being replaced by an almost similar number of previous never users initiating VMS, leading to a relatively  
178 stable number of VMS users. Conversely, the prevalence of DS use decreased significantly.

179 *Trends and determinants of vitamin/mineral supplement use*

180           Several cross-sectional and prospective studies have shown an increase in VMS use in the general  
181 population or in specific groups. In this study, VMS was relatively stable, the large number of participants  
182 discontinuing being compensated by an almost similar number of participants initiating VMS use.  
183 Interestingly, a large fraction of initiators was due to calcium and vitamin D combinations and not to generic

184 VMS, suggesting that this increase was medically driven. These findings are partly in agreement with a  
185 previous study <sup>15</sup>, with the difference that in the previous study the number of participants initiating VMS  
186 outweighed the number of participants discontinuing. Overall, our results indicate that individuals can be  
187 categorized either as VMS users or never users depending on the study period, and that VMS continuers are  
188 only a small fraction of prevalent VMS users.

189 Women and older age were significantly associated with both initiating and continuing VMS use, a  
190 finding in agreement with the literature <sup>15</sup>. A first explanation is that women and elderly people tend to be  
191 more health conscious and to adopt health-promoting behaviours such as VMS use. Another explanation is  
192 the prevention of osteoporosis in elderly women by vitamin D + calcium combinations. Indeed, among  
193 women, 273 (10.9% of all women, 71.6% of all women initiators) initiated the vitamin D + calcium  
194 combination, versus 63 (2.5% of all women, 11.3% of all women discontinuers) who discontinued. Thus, and  
195 in agreement with another study <sup>16</sup>, our results suggest that most women VMS initiators did so for a medical  
196 and not for a personal reason.

197 Being physically active was associated with both the initiation and the continuation of VMS, a  
198 finding also reported elsewhere <sup>15</sup>. Physically active people tend to be more health-conscious and to adopt  
199 more frequently healthy eating and VMS use <sup>21</sup>. Whether physically active people initiated VMS to promote  
200 their health or to improve physical performance remains to be assessed.

201 In the sensitivity analyses, participants of lower education had a lower RRR of inconsistent  
202 (initiating or discontinuing) or consistent (continuing) VMS use, a finding partly in agreement with a  
203 previous study <sup>15</sup>, where such associations were found in men only. Interestingly, when inconsistent users  
204 were split into initiators and discontinuers, the association with education was for discontinuing VMS only.  
205 The lower likelihood of discontinuing VMS among less educated people might be explained by the fact that  
206 participants with higher education consume more non-prescribed medicines <sup>22</sup>, and thus change consumption  
207 more frequently.

208 Presence of disease has been shown to increase the initiation of VMS by patients <sup>15</sup>, although this  
209 statement has been challenged <sup>23</sup>. Still, in this study, no consistent associations were found between self-  
210 reported hypertension, dyslipidemic or diabetic status and initiation of VMS. Interestingly, participants who

211 reported dyslipidemia had a higher RRR of continuing VMS, a finding also reported elsewhere <sup>15</sup>. Although  
212 some studies have shown a small effect of VMS on lipid levels <sup>24</sup> or carotid atherosclerosis <sup>25</sup>, still VMS use  
213 is not recommended for the primary prevention of cardiovascular disease <sup>11</sup>.

#### 214 *Trends and determinants of dietary supplements use*

215 Contrary to a study conducted in the USA <sup>16</sup> but in agreement with another conducted in Scandinavia  
216 <sup>26</sup>, the prevalence of DS users decreased. Possible explanations include the absence or low efficiency of DS  
217 <sup>27-30</sup> and tighter regulations regarding their health claims <sup>31</sup>. Still, it would be of interest that the decrease  
218 observed in this study could be confirmed by other independent studies. As for VMS, our results suggest that  
219 only a small fraction of all DS users continuously consumes them.<sup>45</sup> A possible explanation is that people  
220 adopt DS based on their health promises <sup>32</sup>, then discontinue when these benefits are not met or when side  
221 effects occur <sup>33</sup>. Still, as the reasons for discontinuing were not collected, these explanations remain  
222 speculative. Also, the diversity of DS precluded any analysis of the associations between discontinuing DS  
223 and the type of DS used. Conversely, DS maintenance continuation could be due to the presence of an effect  
224 (or to the absence of adverse effects) of DS. Again, the reasons for continuation are unknown and it would be  
225 of interest that further studies focus on the reasons for initiating, continuing or discontinuing DS.

226 Former smokers were more likely to be discontinuers than never or current smokers. It is possible  
227 that former smokers initially used DS as aid to prevent smoking relapse or to prevent weight gain induced by  
228 quitting smoking, then quit DS due to their relative inefficiency <sup>34, 35</sup>.

229 Physical activity was associated with DS initiation, discontinuing and continuation. If the findings  
230 regarding initiation and continuation are in agreement with the literature <sup>15, 36, 37</sup>, the association of physical  
231 activity with DS discontinuing was unexpected. A possible explanation is that physically active participants  
232 initially relied on DS to boost their performances and discontinued if the DS did not meet their expectations.  
233 As no information was collected regarding the reasons for discontinuing, this explanation should be  
234 confirmed in other studies.

#### 235 *Implications for public health nutrition*

236 Our findings have several implications for public health nutrition. First, they confirm that both VMS  
237 and DS use is an unstable behaviour and that a sizable fraction of that discontinuers are replaced by

238 initiators. Thus, the overall effect of VMS or DS use on health outcomes might be considerably decreased.  
239 Indeed, our results may partly explain the lack of effect of VMS on mortality <sup>9</sup>, as VMS intake might not  
240 have been consistent throughout the study period. Finally, the “cycling” of VMS or DS could also lead to the  
241 sporadic occurrence of side effects due to interactions of VMS or DS with prescribed drugs, with potentially  
242 major health consequences <sup>38</sup>.

#### 243 *Study limitations*

244 This study has several limitations worth acknowledging. First, excluded participants differed  
245 significantly from the included ones. Thus, it is likely that our results are based on a more health-conscious  
246 sample than the general population and that the prevalence estimates for VMS and DS use might be  
247 overestimated. Still, our drop-out rate (24.4%) is comparable to the one of a previous study assessing trends  
248 in VMS use (23.1%) <sup>15</sup>. Second, no data on duration or amount of VMS or DS use was collected; hence, it is  
249 possible that our estimates for the prevalence of continuers might be overestimated, as during the follow-up  
250 period some participants could have undergone several cycles of use/non-use of VMS or DS. Thus, future  
251 studies should consider the number and duration of use/non-use cycles when assessing VMS or DS use.  
252 Third, no information was collected regarding the type, intensity, duration and patterns of physical activity,  
253 and only the status of being physically active was collected; hence, it is likely that this assessment might be  
254 too weak to draw precise conclusions regarding the impact of physical activity on VMS or DS changes. Still,  
255 physical activity was significantly associated with initiation of VMS or DS, suggesting that even raw  
256 evaluations of physical activity status can be used in such studies. Fourth, changes in the baseline  
257 independent variables during follow-up (i.e. age, educational level, BMI changes) were not taken into  
258 account in the multinomial logistic model; still using time varying variables would preclude comparison with  
259 similar studies <sup>15, 38</sup> and could differ according to the criteria used to define change (i.e. in BMI levels) <sup>39</sup>.  
260 Finally, only data from Caucasian participants living in a Swiss city was available, and it is currently  
261 unknown if our findings apply to other ethnicities or to other countries; for instance, a prospective study  
262 conducted in UK women <sup>40</sup> showed a much higher frequency of consistent users (54%, vs. 8.6% in our  
263 study), while the frequency of inconsistent (initiation + discontinuation) users was comparable (25%, vs.  
264 23.6% in our study). Thus, the prevalence of never users, initiators, discontinuers and continuers might not

265 be comparable between countries. Still, as the factors associated with VMS and DS use appear to be  
266 independent of the cultural and ethnic context<sup>36,37</sup>, they might be extrapolated to other countries.

## 267 *Conclusion*

268 In this population-based sample of the city of Lausanne, the prevalence of VMS use remained stable,  
269 but this apparent stability was due to high and comparable discontinuing and initiation rates. Conversely, DS  
270 use appears to be decreasing. Being physically active favours the initiation of VMS or DS, and older age  
271 favours the initiation of VMS.

## 272 **ACKNOWLEDGEMENTS**

273 The CoLaus study was and is supported by research grants from GlaxoSmithKline (no grant  
274 number), the Faculty of Biology and Medicine of Lausanne (no grant number), and the Swiss National  
275 Science Foundation (grants number 33CSCO-122661, 33CS30-139468 and 33CS30-148401). The funding  
276 sources had no involvement in study design; in the collection, analysis and interpretation of data; in the  
277 writing of the report; and in the decision to submit the article for publication.

## 278 **CONFLICT OF INTEREST**

279 PV and GW received funding from the Swiss National Science Foundation (Bern, Switzerland);  
280 GlaxoSmithKline (Philadelphia, PA, USA) and the Faculty of Biology and Medicine of Lausanne (Lausanne,  
281 Switzerland) to conduct the CoLaus study. PMV indicates no conflict of interest.

## 282 **AUTHORS' CONTRIBUTIONS**

283 PMV designed and conducted research, analyzed data and wrote paper; PV and GW provided  
284 essential materials and revised the article for important intellectual content. PMV had primary responsibility  
285 for final content, had full access to the data and is the guarantor of the study. All authors have read and  
286 approved the manuscript.

## 287 **ACKNOWLEDGEMENTS**

288 The CoLaus study was and is supported by research grants from GlaxoSmithKline (no grant  
289 number), the Faculty of Biology and Medicine of Lausanne (no grant number), and the Swiss National  
290 Science Foundation (grants number 33CSCO-122661, 33CS30-139468 and 33CS30-148401). The funding

291 sources had no involvement in study design; in the collection, analysis and interpretation of data; in the  
292 writing of the report; and in the decision to submit the article for publication.

## 293 REFERENCES

- 294 1. Skeie G, Braaten T, Hjartaker A, Lentjes M, Amiano P, Jakšzyn P *et al*. Use of dietary supplements in  
295 the European Prospective Investigation into Cancer and Nutrition calibration study. *Eur J Clin Nutr*  
296 2009; **63 Suppl 4**: S226-238. e-pub ahead of print 2009/11/06; doi: 10.1038/ejcn.2009.83
- 297
- 298 2. Lin JR, Lin YS, Kao MD, Yang YH, Pan WH. Use of supplements by Taiwanese adults aged 19-44  
299 during 2005-2008. *Asia Pac J Clin Nutr* 2011; **20**(2): 319-326. e-pub ahead of print 2011/06/15;
- 300
- 301 3. Timbo BB, Ross MP, McCarthy PV, Lin CT. Dietary supplements in a national survey: Prevalence of  
302 use and reports of adverse events. *J Am Diet Assoc* 2006; **106**(12): 1966-1974. e-pub ahead of print  
303 2006/11/28; doi: 10.1016/j.jada.2006.09.002
- 304
- 305 4. Imai T, Nakamura M, Ando F, Shimokata H. Dietary supplement use by community-living population  
306 in Japan: data from the National Institute for Longevity Sciences Longitudinal Study of Aging (NILS-  
307 LSA). *J Epidemiol* 2006; **16**(6): 249-260. e-pub ahead of print 2006/11/07;
- 308
- 309 5. Guo X, Willows N, Kuhle S, Jhangri G, Veugelers PJ. Use of vitamin and mineral supplements among  
310 Canadian adults. *Can J Public Health* 2009; **100**(5): 357-360. e-pub ahead of print 2009/12/10;
- 311
- 312 6. McCormick DB. Vitamin/mineral supplements: of questionable benefit for the general population.  
313 *Nutr Rev* 2010; **68**(4): 207-213. e-pub ahead of print 2010/04/27; doi: 10.1111/j.1753-  
314 4887.2010.00279.x
- 315
- 316 7. Ford JA, MacLennan GS, Avenell A, Bolland M, Grey A, Witham M *et al*. Cardiovascular disease and  
317 vitamin D supplementation: trial analysis, systematic review, and meta-analysis. *Am J Clin Nutr*  
318 2014; **100**(3): 746-755. e-pub ahead of print 2014/07/25; doi: 10.3945/ajcn.113.082602
- 319
- 320 8. Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E *et al*. Effects of folic acid  
321 supplementation on overall and site-specific cancer incidence during the randomised trials: meta-

- 322 analyses of data on 50,000 individuals. *Lancet* 2013; **381**(9871): 1029-1036. e-pub ahead of print  
323 2013/01/29; doi: 10.1016/S0140-6736(12)62001-7
- 324
- 325 9. Macpherson H, Pipingas A, Pase MP. Multivitamin-multimineral supplementation and mortality: a  
326 meta-analysis of randomized controlled trials. *Am J Clin Nutr* 2013; **97**(2): 437-444. e-pub ahead of  
327 print 2012/12/21; doi: 10.3945/ajcn.112.049304
- 328
- 329 10. Mursu J, Robien K, Harnack LJ, Park K, Jacobs DR, Jr. Dietary supplements and mortality rate in  
330 older women: the Iowa Women's Health Study. *Arch Intern Med* 2011; **171**(18): 1625-1633. e-pub  
331 ahead of print 2011/10/12; doi: 10.1001/archinternmed.2011.445
- 332
- 333 11. Moyer VA, Force USPST. Vitamin, mineral, and multivitamin supplements for the primary  
334 prevention of cardiovascular disease and cancer: U.S. Preventive services Task Force  
335 recommendation statement. *Ann Intern Med* 2014; **160**(8): 558-564. e-pub ahead of print  
336 2014/02/26; doi: 10.7326/M14-0198
- 337
- 338 12. Savikko N, Pitkala KH, Laurila JV, Suominen MH, Tilvis RS, Kautiainen H *et al.* Secular trends in the  
339 use of vitamins, minerals and fish-oil products in two cohorts of community-dwelling older people  
340 in helsinki--population-based surveys in 1999 and 2009. *J Nutr Health Aging* 2014; **18**(2): 150-154.  
341 e-pub ahead of print 2014/02/14; doi: 10.1007/s12603-013-0381-4
- 342
- 343 13. Dickinson A, Blatman J, El-Dash N, Franco JC. Consumer usage and reasons for using dietary  
344 supplements: report of a series of surveys. *J Am Coll Nutr* 2014; **33**(2): 176-182. e-pub ahead of  
345 print 2014/04/15; doi: 10.1080/07315724.2013.875423
- 346
- 347 14. Kim HJ, Giovannucci E, Rosner B, Willett WC, Cho E. Longitudinal and secular trends in dietary  
348 supplement use: Nurses' Health Study and Health Professionals Follow-Up Study, 1986-2006. *J Acad  
349 Nutr Diet* 2014; **114**(3): 436-443. e-pub ahead of print 2013/10/15; doi: 10.1016/j.jand.2013.07.039
- 350
- 351 15. Li K, Kaaks R, Linseisen J, Rohrmann S. Consistency of vitamin and/or mineral supplement use and  
352 demographic, lifestyle and health-status predictors: findings from the European Prospective

- 353 Investigation into Cancer and Nutrition (EPIC)-Heidelberg cohort. *Br J Nutr* 2010; **104**(7): 1058-  
354 1064. e-pub ahead of print 2010/05/06; doi: 10.1017/S0007114510001728
- 355
- 356 16. Knudtson MD, Klein R, Lee KE, Reinke JO, Danforth LG, Wealti AM *et al.* A longitudinal study of  
357 nonvitamin, nonmineral supplement use: prevalence, associations, and survival in an aging  
358 population. *Ann Epidemiol* 2007; **17**(12): 933-939. e-pub ahead of print 2007/09/25; doi:  
359 10.1016/j.annepidem.2007.07.098
- 360
- 361 17. Marques-Vidal P, Pecoud A, Hayoz D, Paccaud F, Mooser V, Waeber G *et al.* Prevalence and  
362 characteristics of vitamin or dietary supplement users in Lausanne, Switzerland: the CoLaus study.  
363 *Eur J Clin Nutr* 2009; **63**(2): 273-281. e-pub ahead of print 2007/10/18; doi:  
364 10.1038/sj.ejcn.1602932
- 365
- 366 18. Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D *et al.* The CoLaus study: a  
367 population-based study to investigate the epidemiology and genetic determinants of cardiovascular  
368 risk factors and metabolic syndrome. *BMC cardiovascular disorders* 2008; **8**: 6. doi: 10.1186/1471-  
369 2261-8-6
- 370
- 371 19. Christe V, Waeber G, Vollenweider P, Marques-Vidal P. Antihypertensive drug treatment changes in  
372 the general population: the CoLaus study. *BMC Pharmacol Toxicol* 2014; **15**: 20. e-pub ahead of  
373 print 2014/04/02; doi: 10.1186/2050-6511-15-20
- 374
- 375 20. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifiro G, Cricelli C *et al.* Patterns of  
376 persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a  
377 retrospective cohort study in primary care. *J Hypertens* 2005; **23**(11): 2093-2100. e-pub ahead of  
378 print 2005/10/07;
- 379
- 380 21. Rautiainen S, Wang L, Gaziano JM, Sesso HD. Who uses multivitamins? A cross-sectional study in  
381 the Physicians' Health Study. *Eur J Nutr* 2014; **53**(4): 1065-1072. e-pub ahead of print 2013/10/31;  
382 doi: 10.1007/s00394-013-0608-5
- 383

- 384 22. Mayer S, Osterle A. Socioeconomic determinants of prescribed and non-prescribed medicine  
385 consumption in Austria. *Eur J Public Health* 2015; **25**(4): 597-603. e-pub ahead of print 2014/11/15;  
386 doi: 10.1093/eurpub/cku179
- 387
- 388 23. Rovira MA, Grau M, Castaner O, Covas MI, Schroder H, Investigators R. Dietary supplement use and  
389 health-related behaviors in a Mediterranean population. *J Nutr Educ Behav* 2013; **45**(5): 386-391. e-  
390 pub ahead of print 2012/12/12; doi: 10.1016/j.jneb.2012.03.007
- 391
- 392 24. Farvid MS, Siassi F, Jalali M, Hosseini M, Saadat N. The impact of vitamin and/or mineral  
393 supplementation on lipid profiles in type 2 diabetes. *Diabetes Res Clin Pract* 2004; **65**(1): 21-28. e-  
394 pub ahead of print 2004/05/28; doi: 10.1016/j.diabres.2003.11.009
- 395
- 396 25. Salonen RM, Nyyssonen K, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Rissanen TH *et al.* Six-  
397 year effect of combined vitamin C and E supplementation on atherosclerotic progression: the  
398 Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. *Circulation* 2003; **107**(7):  
399 947-953. e-pub ahead of print 2003/02/26;
- 400
- 401 26. Waaseth M, Eggen AE, Grimsgaard S. Natural remedies in Scandinavia—authorization and sales.  
402 *Pharm World Sci* 2007; **29**(3): 137-145. e-pub ahead of print 2007/02/13; doi: 10.1007/s11096-006-  
403 9033-7
- 404
- 405 27. Andres M, Sivera F, Falzon L, Buchbinder R, Carmona L. Dietary supplements for chronic gout.  
406 *Cochrane Database Syst Rev* 2014; **10**: CD010156. e-pub ahead of print 2014/10/08; doi:  
407 10.1002/14651858.CD010156.pub2
- 408
- 409 28. Miller BJ, Murray L, Beckmann MM, Kent T, Macfarlane B. Dietary supplements for preventing  
410 postnatal depression. *Cochrane Database Syst Rev* 2013; **10**: CD009104. e-pub ahead of print  
411 2013/10/26; doi: 10.1002/14651858.CD009104.pub2
- 412
- 413 29. Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic  
414 eczema. *Cochrane Database Syst Rev* 2012; **2**: CD005205. e-pub ahead of print 2012/02/18; doi:  
415 10.1002/14651858.CD005205.pub3

- 416
- 417 30. Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C. Antioxidant supplements for  
418 liver diseases. *Cochrane Database Syst Rev* 2011; (3): CD007749. e-pub ahead of print 2011/03/18;  
419 doi: 10.1002/14651858.CD007749.pub2
- 420
- 421 31. Vero V, Gasbarrini A. The EFSA health claims 'learning experience'. *Int J Food Sci Nutr* 2012; **63**  
422 **Suppl 1**: 14-16. e-pub ahead of print 2011/11/18; doi: 10.3109/09637486.2011.633899
- 423
- 424 32. Droz N, Marques-Vidal P. Selling dreams: an overview of slimming products' advertisements in  
425 Switzerland. *Obes Facts* 2014; **7**(5): 282-288. e-pub ahead of print 2014/10/04; doi:  
426 10.1159/000368446
- 427
- 428 33. Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity.  
429 *Aliment Pharmacol Ther* 2013; **37**(1): 3-17. e-pub ahead of print 2012/11/06; doi:  
430 10.1111/apt.12109
- 431
- 432 34. Sood A, Ebbert JO, Prasad K, Croghan IT, Bauer B, Schroeder DR. A randomized clinical trial of St.  
433 John's wort for smoking cessation. *J Altern Complement Med* 2010; **16**(7): 761-767. e-pub ahead of  
434 print 2010/07/02; doi: 10.1089/acm.2009.0445
- 435
- 436 35. Parsons A, Ingram J, Inglis J, Aveyard P, Johnstone E, Brown K *et al*. A proof of concept randomised  
437 placebo controlled factorial trial to examine the efficacy of St John's wort for smoking cessation and  
438 chromium to prevent weight gain on smoking cessation. *Drug Alcohol Depend* 2009; **102**(1-3): 116-  
439 122. e-pub ahead of print 2009/03/31; doi: 10.1016/j.drugalcdep.2009.02.006
- 440
- 441 36. Kim J, Lee JS, Shin A, Kang MH, Shin DS, Chung HR *et al*. Sociodemographic and lifestyle factors are  
442 associated with the use of dietary supplements in a Korean population. *J Epidemiol* 2010; **20**(3):  
443 197-203. e-pub ahead of print 2010/04/23;
- 444
- 445 37. Reinert A, Rohrmann S, Becker N, Linseisen J. Lifestyle and diet in people using dietary  
446 supplements: a German cohort study. *Eur J Nutr* 2007; **46**(3): 165-173. e-pub ahead of print  
447 2007/03/23; doi: 10.1007/s00394-007-0650-2

448

449 38. Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in Prescription and Over-the-  
450 Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs  
451 2011. *JAMA Intern Med* 2016; **176**(4): 473-482. e-pub ahead of print 2016/03/22; doi:  
452 10.1001/jamainternmed.2015.8581

453

454 39. Guerra F, Stringhini S, Vollenweider P, Waeber G, Marques-Vidal P. Socio-demographic and  
455 behavioural determinants of weight gain in the Swiss population. *BMC Public Health* 2015; **15**: 73.  
456 e-pub ahead of print 2015/02/01; doi: 10.1186/s12889-015-1451-9


457

458 40. Hutchinson J, Burley VJ, Greenwood DC, Cade JE. General supplement use, subsequent use and  
459 cancer risk in the UK Women's Cohort Study. *Eur J Clin Nutr* 2014; **68**(10): 1095-1100. e-pub ahead  
460 of print 2014/05/08; doi: 10.1038/ejcn.2014.85

461

462

**Figure 1:** selection procedure.



**Table 1:** multivariable associations between socio-demographic and clinical variables with changes in vitamin supplement use occurring between 2003-6 and 2009-12, CoLaus study, Lausanne, Switzerland, all participants.

	<b>Initiators</b>	<b>Discontinuers</b>	<b>Continuers</b>
N	545	559	404
Gender (man vs. woman)	0.37 (0.30 - 0.46) ***	0.38 (0.31 - 0.47) ***	0.22 (0.17 - 0.29) ***
Age groups			
[35-45[	1 (ref.)	1 (ref.)	1 (ref.)
[45-55[	1.80 (1.38 - 2.36) ***	1.04 (0.82 - 1.31)	2.09 (1.44 - 3.04) ***
[55-65[	2.25 (1.71 - 2.96) ***	0.99 (0.77 - 1.28)	4.56 (3.19 - 6.50) ***
[65+	2.36 (1.70 - 3.28) ***	1.10 (0.80 - 1.53)	6.35 (4.28 - 9.44) ***
Education			
University	1 (ref.)	1 (ref.)	1 (ref.)
High school	0.99 (0.75 - 1.31)	0.77 (0.59 - 1.01)	1.03 (0.75 - 1.42)
Apprenticeship	0.81 (0.62 - 1.06)	0.78 (0.60 - 1.00) *	0.66 (0.48 - 0.91) **
Mandatory	0.85 (0.61 - 1.17)	0.57 (0.41 - 0.78) ***	0.52 (0.35 - 0.78) ***
Marital status (married/cohab vs. other)	0.81 (0.66 - 0.98) *	0.89 (0.73 - 1.08)	0.78 (0.62 - 0.98)
Born in Switzerland vs. other country	1.16 (0.94 - 1.44)	1.04 (0.85 - 1.28)	1.23 (0.96 - 1.59)
Smoking			
Never	1 (ref.)	1 (ref.)	1 (ref.)
Former	1.05 (0.85 - 1.31)	1.21 (0.97 - 1.49)	1.29 (1.00 - 1.66)
Current	0.95 (0.75 - 1.21)	0.98 (0.78 - 1.25)	1.05 (0.79 - 1.41)
Physically active (yes vs. no)	1.30 (1.07 - 1.59) **	1.05 (0.87 - 1.28)	1.44 (1.13 - 1.82) **

BMI groups			
Normal + underweight	1 (ref.)	1 (ref.)	1 (ref.)
Overweight	0.82 (0.66 - 1.02)	0.83 (0.67 - 1.02)	0.68 (0.53 - 0.88) **
Obese	0.81 (0.60 - 1.10)	0.59 (0.42 - 0.82) **	0.65 (0.45 - 0.94) *
Hypertension (yes vs. no)	1.14 (0.91 - 1.44)	1.11 (0.87 - 1.41)	0.88 (0.67 - 1.15)
Dyslipidemia (yes vs. no)	0.89 (0.70 - 1.13)	1.08 (0.85 - 1.37)	1.34 (1.04 - 1.73) *
Diabetes (yes vs. no)	1.53 (0.99 - 2.37)	1.08 (0.65 - 1.81)	1.29 (0.75 - 2.21)

Results are expressed as relative risk ratio and (95% confidence interval). BMI, body mass index. Statistical analysis by multinomial logistic regression using never users as reference. \*, p<0.05; \*\*, p<0.01; \*\*\*, p<0.001.

**Table 2:** multivariable associations between socio-demographic and clinical variables with changes in dietary supplement use occurring between 2003-6 and 2009-12, CoLaus study, Lausanne, Switzerland, all participants.

	Initiators	Discontinuers	Continuers
N	239	405	81
Gender (man vs. woman)	0.41 (0.30 - 0.56) ***	0.30 (0.23 - 0.39) ***	0.30 (0.17 - 0.53) *
Age groups			
[35-45[	1 (ref.)	1 (ref.)	1 (ref.)
[45-55[	1.38 (0.95 - 1.99)	1.47 (1.09 - 1.97) **	2.42 (1.10 - 5.35) *
[55-65[	1.76 (1.22 - 2.55) **	1.77 (1.31 - 2.39) ***	4.53 (2.13 - 9.65) ***
[65+	1.14 (0.70 - 1.87)	1.57 (1.09 - 2.27) *	3.14 (1.29 - 7.62) **
Education			
University	1 (ref.)	1 (ref.)	1 (ref.)
High school	1.02 (0.70 - 1.49)	0.99 (0.73 - 1.35)	1.04 (0.53 - 2.03)
Apprenticeship	0.76 (0.52 - 1.10)	0.79 (0.59 - 1.07)	0.88 (0.46 - 1.68)
Mandatory	0.73 (0.45 - 1.18)	0.77 (0.53 - 1.11)	0.82 (0.36 - 1.84)
Marital status (married/cohab vs. other)	0.75 (0.57 - 0.99) *	1.07 (0.85 - 1.33)	0.81 (0.51 - 1.29)
Born in Switzerland vs. other country	1.37 (1.00 - 1.87) §	1.30 (1.02 - 1.66) *	1.23 (0.73 - 2.08)
Smoking			
Never	1 (ref.)	1 (ref.)	1 (ref.)
Former	1.22 (0.91 - 1.65)	1.31 (1.03 - 1.66) *	1.34 (0.81 - 2.21)
Current	0.75 (0.52 - 1.08)	0.92 (0.69 - 1.21)	0.88 (0.48 - 1.64)
Physically active (yes vs. no)	1.66 (1.23 - 2.24) ***	1.33 (1.06 - 1.66) *	1.84 (1.09 - 3.09) *

BMI groups			
Normal + underweight	1 (ref.)	1 (ref.)	1 (ref.)
Overweight	0.71 (0.52 - 0.98) *	1.00 (0.79 - 1.28)	0.75 (0.45 - 1.27)
Obese	0.82 (0.52 - 1.30)	0.80 (0.55 - 1.16)	0.65 (0.29 - 1.46)
Hypertension (yes vs. no)	0.77 (0.53 - 1.11)	0.91 (0.70 - 1.20)	0.96 (0.55 - 1.67)
Dyslipidemia (yes vs. no)	0.96 (0.68 - 1.35)	1.02 (0.79 - 1.33)	1.24 (0.73 - 2.10)
Diabetes (yes vs. no)	1.38 (0.69 - 2.77)	0.93 (0.51 - 1.70)	0.33 (0.04 - 2.46)

Results are expressed as relative risk ratio and (95% confidence interval). BMI, body mass index. Statistical analysis by multinomial logistic regression using never users as reference. §, p=0.051; \*, p<0.05; \*\*, p<0.01; \*\*\*, p<0.001.

**ONLINE SUPPORTING MATERIAL**

**Supplemental table 1:** comparison of baseline characteristics between included and excluded participants

	<b>Included</b>	<b>Excluded</b>	<b>P-value</b>
N	4676	1508	
Woman	2505 (53.6)	746 (49.5)	0.006
Age (years)	52.6 ± 10.6	54.6 ± 11.3	<0.001
Age groups (%)			<0.001
[35-45[	1362 (29.1)	384 (25.5)	
[45-55[	1365 (29.2)	393 (26.1)	
[55-65[	1288 (27.5)	418 (27.7)	
[65+	661 (14.1)	312 (20.7)	
Education (%)			<0.001
University	939 (20.1)	201 (13.4)	
High school	1185 (25.3)	283 (18.8)	
Apprenticeship	1741 (37.2)	544 (36.2)	
Mandatory	811 (17.3)	475 (31.6)	
Married/cohabiting (%)	3152 (67.4)	982 (65.3)	0.122
Born in Switzerland (%)	3164 (67.7)	838 (55.6)	<0.001
Smoking (%)			<0.001
Never	1889 (40.4)	588 (39.0)	
Former	1580 (33.8)	452 (30.0)	
Current	1207 (25.8)	466 (30.9)	
Physically active (%)	2690 (57.5)	739 (49.1)	<0.001
Body mass index (kg/m <sup>2</sup> )	25.6 ± 4.4	26.5 ± 4.9	<0.001
BMI groups (%)			<0.001
Normal + underweight	2318 (49.6)	651 (43.2)	
Overweight	1705 (36.5)	548 (36.4)	
Obese	653 (14.0)	307 (20.4)	
Self-reported (%)			
Hypertension	1147 (24.5)	483 (32.1)	<0.001
Dyslipidemia	1087 (23.3)	383 (25.4)	0.086
Diabetes	204 (4.4)	106 (7.0)	<0.001
Vitamin supplement use (%)	963 (20.6)	274 (18.2)	0.041
Dietary supplement use (%)	486 (10.4)	128 (8.5)	0.031

Results are expressed as number of participants (percentage) or as average ± standard deviation. BMI, body mass index. Statistical analysis using chi-square or Student's t-test.

**Supplemental table 2:** bivariate associations between socio-demographic and clinical variables with changes in vitamin supplement use occurring between 2003-6 and 2009-12, CoLaus study, Lausanne, Switzerland.

	Never users	Initiators	Discontinuers	Continuers	P-value
N (%)	3168 (67.8)	545 (11.7)	559 (12.0)	404 (8.6)	
Woman (%)	1425 (45.0)	381 (69.9)	379 (67.8)	320 (79.2)	<0.001
Age (years)	51.6 ± 10.5 <sup>a</sup>	55.1 ± 10.1 <sup>b</sup>	51.6 ± 10.6 <sup>a</sup>	58.4 ± 9.4 <sup>c</sup>	<0.001
Age groups (%)					<0.001
[35-45[	1034 (32.6)	102 (18.7)	179 (32.0)	47 (11.6)	
[45-55[	941 (29.7)	166 (30.5)	170 (30.4)	88 (21.8)	
[55-65[	803 (25.4)	183 (33.6)	138 (24.7)	164 (40.6)	
[65+	390 (12.3)	94 (17.3)	72 (12.9)	105 (26.0)	
Education (%)					0.003
University	625 (19.7)	104 (19.1)	134 (24.0)	76 (18.8)	
High school	770 (24.3)	146 (26.8)	139 (24.9)	130 (32.2)	
Apprenticeship	1191 (37.6)	197 (36.2)	210 (37.6)	143 (35.4)	
Mandatory	582 (18.4)	98 (18.0)	76 (13.6)	55 (13.6)	
Married/cohabiting (%)	2236 (70.6)	330 (60.6)	357 (63.9)	229 (56.7)	<0.001
Born in Switzerland (%)	2094 (66.1)	387 (71.0)	385 (68.9)	298 (73.8)	0.004
Smoking (%)					0.195
Never	1266 (40.0)	233 (42.8)	225 (40.3)	165 (40.8)	
Former	1049 (33.1)	183 (33.6)	197 (35.2)	151 (37.4)	
Current	853 (26.9)	129 (23.7)	137 (24.5)	88 (21.8)	
Physically active (%)	1735 (54.8)	345 (63.3)	332 (59.4)	278 (68.8)	<0.001

Body mass index (kg/m <sup>2</sup> )	25.9 ± 4.3 <sup>a</sup>	25.3 ± 4.8 <sup>b</sup>	24.8 ± 4.3 <sup>b</sup>	24.7 ± 4.5 <sup>b</sup>	<0.001
BMI groups (%)					<0.001
Normal + underweight	1463 (46.2)	293 (53.8)	323 (57.8)	239 (59.2)	
Overweight	1230 (38.8)	175 (32.1)	182 (32.6)	118 (29.2)	
Obese	475 (15.0)	77 (14.1)	54 (9.7)	47 (11.6)	
Self-reported (%)					
Hypertension	771 (24.3)	149 (27.3)	126 (22.5)	101 (25.0)	0.304
Dyslipidemia	727 (23.0)	120 (22.0)	120 (21.5)	120 (29.7)	0.011
Diabetes	136 (4.3)	30 (5.5)	19 (3.4)	19 (4.7)	0.377

Results are expressed as number of participants (percentage) or as mean± standard deviation. BMI, body mass index. Statistical analysis using chi-square or analysis of variance. For continuous variables, post-hoc pairwise comparisons using the method of Scheffe were performed when the results of the ANOVA were statistically significant. Results with differing subscripts are significantly different at a p<0.05 level (corrected for multiple comparisons).

**Supplemental table 3:** bivariate associations between socio-demographic and clinical variables with changes in dietary supplement use occurring between 2003-6 and 2009-12, CoLaus study, Lausanne, Switzerland.

	<b>Never users</b>	<b>Initiators</b>	<b>Discontinuers</b>	<b>Continuers</b>	<b>P-value</b>
N (%)	3951 (84.5)	239 (5.1%)	405 (8.7)	81 (1.7)	
Woman (%)	1959 (49.6)	174 (72.8)	308 (76.1)	64 (79.0)	<0.001
Age (years)	52.2 ± 10.6 <sup>a</sup>	53.7 ± 9.9 <sup>b</sup>	54.5 ± 10.2 <sup>b</sup>	56.5 ± 9.7 <sup>b</sup>	<0.001
Age groups (%)					<0.001
[35-45[	1211 (30.7)	56 (23.4)	86 (21.2)	9 (11.1)	
[45-55[	1152 (29.2)	71 (29.7)	121 (29.9)	21 (25.9)	
[55-65[	1034 (26.2)	83 (34.7)	134 (33.1)	37 (45.7)	
[65+	554 (14.0)	29 (12.1)	64 (15.8)	14 (17.3)	
Education (%)					0.285
University	788 (19.9)	54 (22.6)	82 (20.3)	15 (18.5)	
High school	975 (24.7)	72 (30.1)	115 (28.4)	23 (28.4)	
Apprenticeship	1482 (37.5)	82 (34.3)	146 (36.1)	31 (38.3)	
Mandatory	706 (17.9)	31 (13.0)	62 (15.3)	12 (14.8)	
Married/cohabiting (%)	2707 (68.5)	138 (57.7)	261 (64.4)	46 (56.8)	<0.001
Born in Switzerland (%)	2630 (66.6)	178 (74.5)	296 (73.1)	60 (74.1)	0.003
Smoking (%)					0.016
Never	1590 (40.2)	102 (42.7)	164 (40.5)	33 (40.7)	
Former	1302 (33.0)	91 (38.1)	155 (38.3)	32 (39.5)	
Current	1059 (26.8)	46 (19.3)	86 (21.2)	16 (19.8)	
Physically active (%)	2194 (55.5)	170 (71.1)	266 (65.7)	60 (74.1)	<0.001

Body mass index (kg/m <sup>2</sup> )	25.8 ± 4.4 <sup>a</sup>	24.7 ± 4.7 <sup>b</sup>	24.9 ± 4.2 <sup>b</sup>	24.5 ± 4.7 <sup>a, b</sup>	<0.001
BMI groups (%)					<0.001
Normal + underweight	1897 (48.0)	148 (61.9)	224 (55.3)	49 (60.5)	
Overweight	1481 (37.5)	63 (26.4)	137 (33.8)	24 (29.6)	
Obese	573 (14.5)	28 (11.7)	44 (10.9)	8 (9.9)	
Self-reported (%)					
Hypertension	990 (25.1)	46 (19.3)	91 (22.5)	20 (24.7)	0.163
Dyslipidemia	924 (23.4)	49 (20.5)	92 (22.7)	22 (27.2)	0.612
Diabetes	180 (4.6)	10 (4.2)	13 (3.2)	1 (1.2)	NA

Results are expressed as number of participants (percentage) or as mean± standard deviation. BMI, body mass index, NA, not assessable. Statistical analysis using chi-square or analysis of variance. For continuous variables, post-hoc pairwise comparisons using the method of Scheffe were performed when the results of the ANOVA were statistically significant. Results with differing subscripts are significantly different at a p<0.05 level (corrected for multiple comparisons)

**Supplemental table 4:** bivariate associations between socio-demographic and clinical variables with changes in vitamin supplement use occurring between 2003-6 and 2009-12, CoLaus study, Lausanne, Switzerland.

	Never	Inconsistent	Consistent	P-value
N (%)	3168 (67.8)	1104 (23.6)	404 (8.6)	
Woman (%)	1425 (45.0)	760 (68.8)	320 (79.2)	<0.001
Age (years)	51.6 ± 10.5	53.3 ± 10.5	58.4 ± 9.4	<0.001
Age groups (%)				<0.001
[35-45[	1034 (32.6)	281 (25.5)	47 (11.6)	
[45-55[	941 (29.7)	336 (30.4)	88 (21.8)	
[55-65[	803 (25.4)	321 (29.1)	164 (40.6)	
[65+	390 (12.3)	166 (15.0)	105 (26.0)	
Education (%)				0.007
University	625 (19.7)	238 (21.6)	76 (18.8)	
High school	770 (24.3)	285 (25.8)	130 (32.2)	
Apprenticeship	1191 (37.6)	407 (36.9)	143 (35.4)	
Mandatory	582 (18.4)	174 (15.8)	55 (13.6)	
Married/cohabiting (%)	2236 (70.6)	687 (62.2)	229 (56.7)	<0.001
Born in Switzerland (%)	2094 (66.1)	772 (69.9)	298 (73.8)	0.002
Smoking (%)				0.095
Never	1266 (40.0)	458 (41.5)	165 (40.8)	
Former	1049 (33.1)	380 (34.4)	151 (37.4)	
Current	853 (26.9)	266 (24.1)	88 (21.8)	
Physically active (%)	1735 (54.8)	677 (61.3)	278 (68.8)	<0.001
Body mass index (kg/m <sup>2</sup> )	25.9 ± 4.3	25.1 ± 4.6	24.7 ± 4.5	<0.001
BMI groups (%)				<0.001
Normal + underweight	1463 (46.2)	616 (55.8)	239 (59.2)	
Overweight	1230 (38.8)	357 (32.3)	118 (29.2)	
Obese	475 (15.0)	131 (11.9)	47 (11.6)	
Self-reported (%)				
Hypertension	771 (24.3)	275 (24.9)	101 (25.0)	0.906
Dyslipidemia	727 (23.0)	240 (21.7)	120 (29.7)	0.004
Diabetes	136 (4.3)	49 (4.4)	19 (4.7)	0.921

Results are expressed as number of participants (percentage) or as average ± standard deviation. BMI, body mass index. Inconsistent=initiating or discontinuing; consistent=continuing. Statistical analysis using chi-square or analysis of variance.

**Supplemental table 5:** multivariable associations between socio-demographic and clinical variables with changes in vitamin supplement use occurring between 2003-6 and 2009-12, CoLaus study, Lausanne, Switzerland, all participants.

	Inconsistent	Consistent
N	1104	404
Gender (man vs. woman)	0.38 (0.32 - 0.44) ***	0.22 (0.17 - 0.29) ***
Age groups		
[35-45[	1 (ref.)	1 (ref.)
[45-55[	1.32 (1.09 - 1.59) **	2.09 (1.44 - 3.03) ***
[55-65[	1.45 (1.19 - 1.77) ***	4.55 (3.19 - 6.50) ***
[65+	1.57 (1.22 - 2.01) ***	6.35 (4.28 - 9.44) ***
Education		
University	1 (ref.)	1 (ref.)
High school	0.87 (0.70 - 1.07)	1.02 (0.74 - 1.41)
Apprenticeship	0.79 (0.65 - 0.96) *	0.66 (0.48 - 0.91) **
Mandatory	0.69 (0.54 - 0.89) **	0.52 (0.35 - 0.77) ***
Marital status (married/cohab vs. other)	0.85 (0.73 - 0.99) *	0.78 (0.63 - 0.98) *
Born in Switzerland vs. in other country	1.10 (0.94 - 1.29)	1.23 (0.96 - 1.59)
Smoking		
Never	1 (ref.)	1 (ref.)
Former	1.13 (0.96 - 1.33)	1.29 (1.01 - 1.66)
Current	0.97 (0.81 - 1.16)	1.05 (0.79 - 1.41)
Physically active (yes vs. no)	1.17 (1.01 - 1.36) *	1.43 (1.13 - 1.82) **
BMI groups		
Normal + underweight	1 (ref.)	1 (ref.)
Overweight	0.82 (0.70 - 0.97)	0.68 (0.53 - 0.88) **
Obese	0.70 (0.55 - 0.89) **	0.64 (0.44 - 0.94) *
Hypertension (yes vs. no)	1.13 (0.94 - 1.35)	0.88 (0.67 - 1.15)
Dyslipidemia (yes vs. no)	0.98 (0.82 - 1.17)	1.34 (1.04 - 1.73) *
Diabetes (yes vs. no)	1.31 (0.92 - 1.88)	1.29 (0.75 - 2.21)

Results are expressed as relative risk ratio and (95% confidence interval). BMI, body mass index.

Inconsistent=initiating or discontinuing; consistent=continuing. Statistical analysis by multinomial logistic regression using never users as reference. \*, p<0.05; \*\*, p<0.01; \*\*\*, p<0.001.

**Supplemental table 6:** bivariate associations between socio-demographic and clinical variables with changes in dietary supplement use occurring between 2003-6 and 2009-12, CoLaus study, Lausanne, Switzerland.

	Never	Inconsistent	Consistent	P-value
N (%)	3951 (84.5)	644 (13.8)	81 (1.7)	
Woman (%)	1959 (49.6)	482 (74.8)	64 (79.0)	<0.001
Age (years)	52.2 ± 10.6	54.2 ± 10.1	56.5 ± 9.7	<0.001
Age groups (%)				<0.001
[35-45[	1211 (30.7)	142 (22.1)	9 (11.1)	
[45-55[	1152 (29.2)	192 (29.8)	21 (25.9)	
[55-65[	1034 (26.2)	217 (33.7)	37 (45.7)	
[65+	554 (14.0)	93 (14.4)	14 (17.3)	
Education (%)				0.139
University	788 (19.9)	136 (21.1)	15 (18.5)	
High school	975 (24.7)	187 (29.0)	23 (28.4)	
Apprenticeship	1482 (37.5)	228 (35.4)	31 (38.3)	
Mandatory	706 (17.9)	93 (14.4)	12 (14.8)	
Married/cohabiting (%)	2707 (68.5)	399 (62.0)	46 (56.8)	0.001
Born in Switzerland (%)	2630 (66.6)	474 (73.6)	60 (74.1)	0.001
Smoking (%)				0.004
Never	1590 (40.2)	266 (41.3)	33 (40.7)	
Former	1302 (33.0)	246 (38.2)	32 (39.5)	
Current	1059 (26.8)	132 (20.5)	16 (19.8)	
Physically active (%)	2194 (55.5)	436 (67.7)	60 (74.1)	
Body mass index (kg/m <sup>2</sup> )	25.8 ± 4.4	24.8 ± 4.4	24.5 ± 4.7	<0.001
BMI groups (%)				<0.001
Normal + underweight	1897 (48.0)	372 (57.8)	49 (60.5)	
Overweight	1481 (37.5)	200 (31.1)	24 (29.6)	
Obese	573 (14.5)	72 (11.2)	8 (9.9)	
Self-reported (%)				
Hypertension	990 (25.1)	137 (21.3)	20 (24.7)	0.117
Dyslipidemia	924 (23.4)	141 (21.9)	22 (27.2)	0.497
Diabetes	180 (4.6)	23 (3.6)	1 (1.2)	NA

Results are expressed as number of participants (percentage) or as mean±standard deviation. BMI, body mass index. Inconsistent=initiating or discontinuing; consistent=continuing. Statistical analysis using chi-square or analysis of variance. NA, not assessable.

**Supplemental table 7:** multivariable associations between socio-demographic and clinical variables with changes in dietary supplement use occurring between 2003-6 and 2009-12, CoLaus study, Lausanne, Switzerland, all participants.

	Inconsistent	Consistent
N	644	81
Gender (man vs. woman)	0.34 (0.28 - 0.41) ***	0.30 (0.17 - 0.53) ***
Age groups		
[35-45[	1 (ref.)	1 (ref.)
[45-55[	1.43 (1.13 - 1.82) **	2.42 (1.10 - 5.35) *
[55-65[	1.76 (1.38 - 2.25) ***	4.53 (2.13 - 9.65) ***
[65+	1.40 (1.03 - 1.90) *	3.14 (1.29 - 7.62) **
Education		
University	1 (ref.)	1 (ref.)
High school	1.00 (0.78 - 1.29)	1.04 (0.53 - 2.03)
Apprenticeship	0.78 (0.61 - 1.00) *	0.88 (0.46 - 1.68)
Mandatory	0.75 (0.56 - 1.02)	0.82 (0.36 - 1.84)
Marital status (married/cohab vs. other)	0.94 (0.78 - 1.12)	0.81 (0.51 - 1.29)
Born in Switzerland vs. other country	1.33 (1.09 - 1.62) **	1.23 (0.73 - 2.08)
Smoking		
Never	1 (ref.)	1 (ref.)
Former	1.28 (1.05 - 1.55) *	1.34 (0.81 - 2.21)
Current	0.85 (0.67 - 1.07)	0.88 (0.48 - 1.64)
Physically active (yes vs. no)	1.44 (1.19 - 1.73) ***	1.84 (1.09 - 3.09) *
BMI groups		
Normal + underweight	1 (ref.)	1 (ref.)
Overweight	0.89 (0.73 - 1.08)	0.75 (0.45 - 1.27)
Obese	0.81 (0.60 - 1.09)	0.65 (0.29 - 1.46)
Hypertension (yes vs. no)	0.86 (0.69 - 1.08)	0.96 (0.55 - 1.67)
Dyslipidemia (yes vs. no)	1.00 (0.80 - 1.24)	1.24 (0.73 - 2.10)
Diabetes (yes vs. no)	1.09 (0.68 - 1.74)	0.33 (0.04 - 2.46)

Results are expressed as relative risk ratio and (95% confidence interval). BMI, body mass index.

Inconsistent=initiating or discontinuing; consistent=continuing. Statistical analysis by multinomial logistic regression using never users as reference. \*, p<0.05; \*\*, p<0.01; \*\*\*, p<0.001.